Document:

Exhibit 10.3

 Exhibit 10.3 
 BPA SUBCONTRACT 
 THIS BPA SUBCONTRACT (this “Subcontract”) is made and entered into
as of the l” day of April, 2005 by and between QuadraMed Corporation, a Delaware corporation, having a place of business at 12110 Sunset Hills Road, Suite 600, Reston, Virginia 20190 (“QuadraMed” or “Licensee”), and Document
Storage Systems, Inc., a Florida corporation having a place of business at 12575 US Hwy I, Suite 200, Juno Beach, FL 33408 (“DSS” or “Licensor”). 
 WITNESSETH 
 WHEREAS, QuadraMed is engaged in providing healthcare
information systems and health information management product suites and services including such major brands as Affinity HIS®; Quantim HIM®; and TempusOne®; and 
 WHEREAS, DSS designs, manufactures, and licenses healthcare software solutions for the healthcare market including one of which QuadraMed has marketed to the Veterans Administration Health Care System as the claim scrubber module of
Encoder Product Suite (“EPS”) defined below 
 WHEREAS, QuadraMed was awarded and administers a United States General
Services Administration (“GSA”) Federal Supply Service Multiple Award Schedule contract identified as GS-35F-0171L and further, under this GSA contract, QuadraMed has been awarded a Blanket Purchase Agreement (“BPA”) Number
101-049AH-005 by the Department of Veterans Affairs that identifies certain products and services available for sale or license, as appropriate, to the Department of Veterans Affairs and/or other United States Government agencies identified in the
BPA (individually or collectively, “Customer”); and 
 WHEREAS, QuadraMed wishes to license certain DSS products and
services for integration and use in its EPS products that are sublicensed to the specific government entities under the BPA and such other services as are necessary to install and maintain and support such EPS products; and 
 WHEREAS, DSS wishes to license its software and provide its Services to QuadraMed for sublicense and resale respectively to Customer, as the
opportunity arises, in accordance with the terms of this Subcontract, which constitutes the entire agreement between the parties with respect to the subject matter of this Agreement. 
 NOW THEREFORE, be it, and it hereby is, agreed that in consideration of the mutual promises set forth herein, the receipt and sufficiency of which
are hereby acknowledged, QuadraMed and DSS agree as follows: 
  

	1.	SCOPE 

 According to the terms and conditions of
this Subcontract, Licensor hereby grants Licensee a nonexclusive, non-transferable, and restricted license to use the product(s) as specified in Exhibit A solely to provide the EPS products to Customer and provide related services to Customer
specified at Exhibit A (collectively “Products”), inclusive of Software in object code form only (“Software”) training, technical and maintenance manuals (“Documentation”), and installation, maintenance and support
services (“Services”), as specifically identified in Exhibit A (collectively “Products”). 
 A. Licensor will
provide pursuant to license under this Subcontract to Licensee, according to a reasonable distribution procedure specified by Licensee, the Products for integration into and sublicense to the Customer solely for QuadraMed’s EPS products
licensed to government entities as specifically identified in and strictly pursuant to the BPA. 
  

 Page 1 of 16 

 B. Licensor will provide pursuant to license under this Subcontract to Licensee, and to
Licensee’s subcontractors, such Products solely to be used as needed for Licensee’s internal use in developing, integrating and supporting the Products solely for the purpose of sublicensing the Product to the Customer as determined by
Licensor. 
  

	2.	TERM 

 A. Initial Term. This
Subcontract shall be effective as of the date first above written (the “Effective Date”) and, unless otherwise terminated in accordance with the provisions hereof, shall remain in effect through the expiration, termination, or cancellation
of the BPA (“Term”). 
 B. GSA Schedule. The underlying QuadraMed GSA Schedule expires on November 10, 2006.
QuadraMed expects GSA to exercise the fiscal year options contained in the QuadraMed GSA Schedule. In the event any option is not exercised, then the BPA will be terminated and this Subcontract similarly terminated subject to the surviving
obligations set forth below. 
 C. Renewal Terms. Unless otherwise terminated in accordance with the terms of this Subcontract,
this Subcontract shall be renewed at the end of the Initial Term, in the event that the BPA is extended by the Customer beyond the Initial Term. If the BPA is extended for an additional term, then at the expiration of the Initial Term this
Subcontract may, subject to Article 2.D below, be renewed and at the end of any renewal term (each a “Renewal Term”), for a period of one year from the execution date or the anniversary date thereof. 
 D. Review of BPA. 
 1.
Notwithstanding the foregoing, in the event an annual review of the BPA by the Department of Veterans Affairs results in a written determination solely by the Department of Veterans Affairs and/or any other agencies of the United States Government
(“Government”), that the BPA or this Subcontract is no longer in the best interest of the Government, and (in the absence of a material breach of this Subcontract by DSS) without a continuation of the BPA by QuadraMed using itself or a
third party to perform DSS’ technological role under this Subcontract, then the BPA and/or this Subcontract may be cancelled by the Customer or by QuadraMed, as the case may be. Upon termination or cancellation of the BPA for any reason other
than a material breach by DSS, QuadraMed must pay all outstanding undisputed invoices as determined pursuant to Section 7(G), and must reimburse those costs directly related to DSS’ performance of orders under this Subcontract, all
incurred in connection with a Purchase Order or Work Order prior to the date of such termination or cancellation that would be permitted under the applicable Federal Acquisition Regulation (“FAR”) for a similarly situated government
contractor. Upon termination, cancellation, or expiration of this Subcontract, DSS shall invoice QuadraMed for any costs or fees owed by QuadraMed under this Subcontract. QuadraMed shall pay any and all undisputed invoiced amounts in full
within thirty (30) days of the date of such invoice. 
 2. To assist QuadraMed in preparing for the Department of Veterans Affairs annual
review QuadraMed and DSS shall perform an annual review to provide QuadraMed with ‘appropriate information for QuadraMed’s use during the Department of Veterans Affairs’ annual review. QuadraMed and DSS shall review whether a need for
the Subcontract still exists and whether this Subcontract would still be considered a Best Value by the Government. DSS shall provide updated price list information in all instances reflecting the continuation of discounts as agreed upon
pursuant to this Subcontract and relied upon 

  

 Page 2 of 16 

 
by QuadraMed in establishing QuadraMed’s pricing in the BPA. Following the Government’s review, QuadraMed shall advise DSS of any decision by the
Government that impacts this Subcontract. 
  

	3.	ORDERS AND DELIVERY 

 A. Purchase
Orders. Upon receipt by QuadraMed of orders for EPS products from the Customer under the BPA, QuadraMed shall order such Products from DSS pursuant to written firm fixed price purchase orders in accordance with the Fees and other prices set
forth in Exhibit B (each, a “Purchase Order”). Each Purchase Order shall contain an order number, the Fees or price, the date of the order, the quantity of Products ordered, the requested delivery date, the term of the license and any
other special conditions of the particular order as agreed to by both parties. All Purchase Orders shall be governed by the terms and conditions of this Subcontract, unless otherwise agreed by both parties in writing. Each Purchase Order that is in
accordance with the terms and conditions of this Subcontract shall be accepted by DSS. All Purchase Orders shall be incorporated into, and made a part of, this Subcontract. 
 B. Delivery. Licensor will deliver the ordered Product, including maintenance updates and Product upgrades within a reasonable time after
general release by DSS, on CD’s to QuadraMed’s specified representative for further integration and sublicense to the Customer in object code only and solely in accordance with this Subcontract. QuadraMed is responsible for delivering the
Product to the Customer in object code form only. Risk of loss of the Product passes to QuadraMed upon delivery to QuadraMed. 
 C.
[Reserved] 
 D. Title and License. Title to the Products, including any and all ownership rights to patents, copyrights,
trademarks, trade secrets, and source code in connection therewith, shall remain the exclusive property of DSS or QuadraMed, as the case may be, in accordance with the ownership rights as they existed on the day before this Subcontract’s
effective date. QuadraMed hereby acknowledges and agrees that QuadraMed shall not have or accrue any title or ownership interests to the Products including any ownership rights to patents, copyrights, trademarks, trade secrets, and source code
therein. The Products shall not be deemed a “work made for hire” under the U.S. Copyright Act, 17 U.S.C. §101, et seq. QuadraMed hereby assigns, transfers and conveys to DSS any and all rights, title and interests QuadraMed may have
or accrue in the Products including (without limitation) any and all copyrights, trade secrets, patents, and source code in connection therewith. QuadraMed shall not remove, alter, cover or obfuscate any appropriate copyright notice or other
proprietary rights notice placed in or on machine language or human readable form as deemed appropriate by DSS in the context of this Subcontract. DSS reserves the right to require QuadraMed to make reasonable changes to such notices, to be
implemented by QuadraMed at the next reasonable opportunity. 
  

	4.	PRICE AND PAYMENT 

 A. Fees for
Products. QuadraMed shall pay DSS the Annual License Fee as set forth on Exhibit B on the Effective Date and on or before each subsequent anniversary of the Effective Date during the Term, including any extensions or renewals thereof. QuadraMed
shall pay DSS the Sublicense Fee for each of the Products licensed by DSS under this Subcontract as set forth in Exhibit B (“Fees”), which is based on either royalties set forth or on other fixed bases such as fixed hourly rates or fixed
price per action. Fees to QuadraMed for the Products are inclusive of all taxes, are in U.S. Dollars, excluding income tax of QuadraMed or any other taxes based on 

  

 Page 3 of 16 

 
QuadraMed’s net income. Fee increases are limited to these set forth in Exhibit B. Any other products or services provided by DSS shall be provided at
the price/fees as set forth in Exhibit B. If such other products or services are not identified in Exhibit B and are not expressly provided free of charge as set forth in this Subcontract, such products or services shall be provided at DSS’
standard time and material rates or fees/prices as applicable. 
 B. Invoicing. DSS will submit an invoice to QuadraMed upon
receipt by DSS of a Purchase Order from QuadraMed for Product. A proper invoice may be prepared on letterhead or standard commercial form, and shall include: (1) DSS’ name and invoice date, (2) The Purchase Order number or Delivery
Order Number; (3) Description of Product licensed or provided, the applicable Customer location, the Fee per Product and the total Fee of the invoice; (4) Credits as applicable; (5) Name (if applicable), title, complete mailing address
where payment is to be sent; and (6) Other substantiating documentation or information as agreed to between the parties. All invoices shall be mailed to the address first written above: Attention: Accounts Payable. 
 C. Payment Terms. Unless otherwise agreed in writing, QuadraMed shall pay the Fees and/or price for Products specified in a proper invoice,
in U.S. Dollars, within ten (10) days after receipt of the related payment from the Customer, not to exceed ninety (90) days after receipt of a proper invoice by QuadraMed. If QuadraMed fails to pay DSS, in whole or in part, within ninety
(90) days after QuadraMed’s receipt of a proper invoice from DSS, QuadraMed will pay DSS interest on the undisputed unpaid balance at the rate of 1% per month until paid. 
  

	5.	LICENSED SOFTWARE 

 The Products and any software
provided herein is licensed to QuadraMed and sublicensed to Customer pursuant to and in strict accordance with the Software License Agreement set forth at Exhibit C (“Software License”) attached hereto and by this reference incorporated
herein. The terms and conditions set forth in the Software License are in addition to, and do not supplant, the terms and conditions set forth in this Subcontract. 
  

	6.	OBLIGATIONS OF THE PARTIES. 

 A.
Noncompete. During the Term of this Subcontract, including any Renewal Term, neither Party shall, independently or as a member of another proposal team, engage in activities that are competitive with the EPS portions provided under this
Subcontract to the Department of Veterans Affairs during the Term, except in the case of the Department of Veterans Affairs directing the use of another 
 B. No Representation. QuadraMed shall not make any representation, guaranty or warranty concerning the Products except as expressly authorized in writing by DSS whether in this Subcontract, in materials
provided by DSS in connection with this Subcontract, or otherwise. 
 C. Price Quotation. QuadraMed will quote only prices,
terms and conditions associated with the DSS Products to the Customer as specified herein. QuadraMed will not make representations with respect to DSS that are not within the reasonable capability of DSS. QuadraMed may assume that any
representations made by DSS in this Subcontract, in materials provided by DSS in connection with this Subcontract, or otherwise in writing, are considered by DSS to be “within the reasonable capability of DSS”. 
  

 Page 4 of 16 

 D. Trade Shows. Upon receipt of a written request from DSS, QuadraMed will assist with
appropriate trade shows. QuadraMed agrees to keep DSS informed of any potential opportunities to display and participate in forthcoming exhibitions. In no event will QuadraMed be liable or responsible for any and all costs incurred by DSS for such
participation. 
 E. Notifications. DSS agrees to permit QuadraMed to use its name, logos, product names, address, telephone
number, and other similar information in all advertisements, mailers, and related promotional materials, as well as on performance-related documentation and client communications. 
 F. Privity. The BPA is a contract by and between QuadraMed and the U. S. Government. Consequently, DSS shall have no direct discussions,
correspondence, meetings, or other similar contacts with the U.S. Government with respect to the BPA except: (1) as authorized by QuadraMed or in conjunction with QuadraMed; and (2) as part of a routine installation/deinstallation or
maintenance of the Products; or (3) as reasonably necessary to enable DSS to perform its duties under this Subcontract. DSS shall not remit invoices to the Customer nor receive any payments from the Customer with respect to the BPA. 

G. Advertisements. DSS shall not use nor make mention of the BPA, this Subcontract, nor the QuadraMed name in any commercial
advertisements or public relations materials without the express written permission of QuadraMed. In the event that such permission is granted, the advertising copy shall not state or imply that (1) the BPA is held by DSS; (2) the DSS
Products are, in any way, endorsed or approved, by the U. S. Government; or (3) the DSS Products furnished under the BPA are considered by the Government to be superior to other similar Products on another BPA or other GSA Schedules.

 H. Unauthorized Use/Access: QuadraMed shall use its reasonable best efforts to prevent unauthorized users from accessing the
Product. QuadraMed shall use its best efforts to prevent unauthorized access to the Product. 
 I. Records, Reports and Audit.
Within thirty (30) days after the end of each calendar quarter, QuadraMed shall forward a report indicating sublicense sales made during such quarter and payment of the applicable fees. QuadraMed shall maintain accurate records relating to
sales of Product so as to establish the Sublicense fee payments due to DSS herein. Such books and records shall be available for a reason stated at their place of keeping for inspection by an independent auditor chosen and paid by DSS during normal
business ours for the purposes of determining whether the correct fees have been paid to DSS. 
 J. Indemnification. Each party
shall indemnify and hold the other party harmless from any liabilities, damages or costs (including reasonable attorneys’ fees), or expense incurred by the indemnified party (“Indemnitee”) for any claim, demand, proceeding or action
based on infringement of a United States patent or copyright as a result of the indemnified party’s or Customer’s use of Software to the extent such claim, demand, proceeding or action is based on any portion(s) of the Software owned or
developed by the indemnifying party (“Indemnitor”), provided that the Indemnitee: (I) has notified Indemnitor promptly in writing of any such claim or suit against Indemnitee or Customer and Indemnitee cooperates fully with
Indemnitor, and permits Indemnitor to defend or settle such claim or suit on behalf of Indemnitee; (2) has not used the Software with other software except as permitted by Indemnitor’s then-current published specifications or by this or
any other valid agreement between the parties; and (3) has complied with all of the terms and conditions of this Subcontract with respect to the Software. Indemnitor shall have no liability or obligation to Indemnitee with respect to any
infringement claim based 

  

 Page 5 of 16 

 
upon (a) the use of a superseded or altered release of the Software or Documentation if the infringement would have been avoided by the use of a current
or an unaltered release of the Software or Documentation that Indemnitor makes available to Indemnitee and Customer; or (b) the combination, operation or use of any Software or Documentation furnished under this Subcontract with software,
hardware or other materials not furnished by Indemnitor if such infringement would have been avoided by the use of the Software or Documentation without such software, hardware or other materials, except where this Subcontract allowed for use with
such software, hardware or other materials. The foregoing states the entire liability of each party with respect to the infringement of any United States patent or copyright by the Software or Documentation it owns or develops. Further, if any
Software becomes or, in Indemnitor’s opinion, is likely to become the subject of any injunction preventing its use as contemplated herein, Indemnitor may, at its option: (a) procure for Indemnitee and/or Customer the right to continue
using such Software; (b) replace or modify such Software so that it becomes non-infringing without substantially compromising its functionality; or, if(a) and (b) are not reasonably available to Indemnitor, then (c) terminate
Indemnitor’s or Customer’s license to the allegedly infringing Software and pay to such licensee(s) an amount not to exceed the amount of license fees paid by such licensee(s) for the license to the applicable Software. 
 K. Documentation: (1) Should DSS develop documentation based upon QuadraMed documentation, DSS will use published formats from
QuadraMed. DSS will review QuadraMed documentation as published from time to time and make updates to DSS-produced documentation as appropriate. DSS will provide draft copies for review by QuadraMed at least two weeks prior to publishing its revised
documentation and will incorporate any QuadraMed feedback before distributing the documentation to Customer. (2) Should QuadraMed develop documentation based upon DSS documentation, QuadraMed will use published formats from DSS. QuadraMed will
review DSS documentation as published from time to time and make updates to QuadraMed-produced documentation as appropriate. QuadraMed will provide draft copies for review by DSS at least two weeks prior to publishing its revised documentation and
will incorporate any DSS feedback before distributing the documentation to Customer. (3) Documentation shall carry a legend noting that QuadraMed and/or DSS as the case may be, is/are the owner(s) of their respective works used to derive the
documentation and that each such owner retains all rights to its intellectual property. 
  

	7.	OBLIGATIONS OF DSS TO PROVIDE SUPPORT 

 A.
Product Maintenance Support. QuadraMed will provide first-level support to the Customer for the Products. DSS shall provide support to QuadraMed in accordance with Exhibit D (“DSS Product Support Services”). 
 B. Technical and Maintenance Manuals. DSS will make available to QuadraMed those training, technical and maintenance manuals regarding their
Products which it has available. All material will be in the English language. Prices for such publications will be DSS’ then-published prices. 
 C. Training and Support. QuadraMed agrees that it will require special assistance from DSS in developing and marketing the Products as agreed to by both parties. During the term of this Subcontract, DSS shall provide QuadraMed
with technical support consisting of: (a) reasonable hardware and software technical consultation, including the designation of a DSS account manager with primary responsibility for support of QuadraMed and (b) routine maintenance and
revision of DSS furnished publications. These DSS activities shall be furnished at no additional cost to QuadraMed. 
  

 Page 6 of 16 

 D. Product Refreshment. DSS agrees to continually develop reasonable product enhancements
to the Product that enable the EPS product to remain competitive in the Department of Veterans Affairs marketplace. Such product enhancements will be provided to QuadraMed at either (as determined by DSS) (1) no additional cost, or
(2) according to a price estimate which includes a complete Statement of Work and which is agreed to by QuadraMed in writing in advance. Should DSS make such enhancements available to its other customers, the price charged to QuadraMed shall
not exceed DSS’ then-current standard fees for its other customers. Any deliverable provided by DSS to QuadraMed pursuant to this section shall be considered Product for purposes of this Subcontract and shall be governed by the protections as
well as the general terms and conditions of this Subcontract. 
 E. Order Assistance. DSS shall provide all essential and
helpful reasonable assistance in the process of accepting Customer orders and providing the current status on each order. 
 F.
Sales Assistance. In the event QuadraMed is invited, or otherwise has the opportunity, to participate in sales meetings for the purpose of making presentations regarding DSS products, DSS may participate in such sales activities at the
invitation of QuadraMed, if DSS so chooses. DSS shall be compensated for any additional services requested by QuadraMed in the nature of special meeting attendance, travel, and other management or technical support (other than ordinary sales and
marketing activity) under the hourly rates and cost coverage provisions of this Subcontract 
 G. Fee Requirement:
Notwithstanding anything to the contrary, if QuadraMed is not current in its payment of undisputed invoices to DSS, DSS may provide written notice to QuadraMed, informing QuadraMed that it is in breach of its payment obligations under this
Subcontract. If, after ninety (90) days after receipt of such notice, QuadraMed has not satisfied its payment obligations, DSS shall be entitled to suspend performance under this Subcontract until such time as QuadraMed is current in payment of
any and all Sublicense Fees for the Products and Annual License Fees. 
  

	8.	WARRANTY. 

 DSS warrants the Products according to
the terms of the Software License Agreement at Exhibit C. 
  

	9.	TRADEMARKS AND TRADENAMES; LABELING. 

 A.
DSS Trademarks. DSS hereby grants to QuadraMed a non exclusive, non-transferable, non-sublicensable worldwide right and license 
 to
promote and advertise itself as having a strategic relationship with DSS using the DSS trade names and trademarks, in each case solely in connection with the marketing and distribution of the Products to Customer under the BPA. When so using such
marks, names and logos, QuadraMed shall comply with DSS’ trademark usage guidelines as may be provided to QuadraMed from time to time. QuadraMed will submit a copy of the proposed use of logo (e.g., screen shot or draft of document) for review
and approval at least two weeks before beginning production. Should DSS change its logo during the term of this Subcontract, QuadraMed shall update its published uses of the logo within ninety (90) days. Publications with the DSS logo shall
note that QuadraMed and DSS are separate companies. 
  

 Page 7 of 16 

 B. Labeling Requirements. DSS shall conspicuously and legibly affix registered patent,
trademark and/or copyright notices from time to time on all Products, promotional and marketing documentation, press releases and other materials relating to Products. 
 C. OuadraMed Trademark. QuadraMed hereby grants to DSS a non-exclusive, nontransferable, non-sublicensable worldwide right and license to promote and advertise itself to agencies of the United States
Government as a supplier to QuadraMed, using the trademarks, trade names and logos that QuadraMed may adopt for EPS products or for QuadraMed at the corporate level from time to time. When so using such marks, names and logos, DSS shall comply with
QuadraMed’s trademark usage guidelines as may be provided to DSS by notice from time to time. DSS will submit a copy of the proposed use of logo (e.g., screen shot or draft of document) for review and approval at least two weeks
before beginning production. Should QuadraMed change its logo during the term of this Subcontract, DSS shall update its published uses of the logo within ninety (90) days. Publications with the QuadraMed logo shall note that QuadraMed and DSS
are separate companies. 
 D. Each party shall obtain the written approval of the other party concerning the content and timing of news
releases, articles, brochures, advertisements, prepared speeches, email bulletins and other information releases, concerning this Subcontract within a reasonable time prior to the release of such information. Such approval shall not unreasonably be
withheld, conditioned or delayed. 
  

	10.	CONFIDENTIALITY. 

 A. Obligations.
QuadraMed acknowledges that the Products contain proprietary and trade secret information of DSS and that DSS may disclose to QuadraMed certain other proprietary and confidential information relating to the business or products of DSS. DSS
acknowledges that QuadraMed may reveal certain proprietary and trade secret information of QuadraMed with respect to QuadraMed’s BPS products, and that QuadraMed may disclose to DSS certain other proprietary and confidential information
relating to the business or products of QuadraMed. Each party agrees to use its best efforts to keep such information of the other party confidential during the Term of this Subcontract and for three (3) years following its expiration or
termination and shall, in any event, use no less than the same degree of care that it uses with its own information, which it designates as confidential. 
 B. Exceptions. The provisions of this section shall not apply to any part of the confidential information of DSS or QuadraMed to the extent that: 
 1. Such information was generally known or was otherwise in the public domain prior to disclosure to the nondisclosing party hereunder, or become so
generally known solely through legal and appropriate means subsequent to such disclosure through no fault of the nondisclosing party; 
 2.
Such information was legally received by the nondisclosing party from a third party not under an obligation to the owner of such information not to disclose it and who received such information through legal means; or 
 3. Such information was independently developed by the nondisclosing party without the benefit of access to the disclosing party’s confidential
information. 
  

 Page 8 of 16 

 C. Classified Information. U.S. Government classified data or information shall be provided
to DSS only as required to satisfy performance of work being accomplished under the terms of this Subcontract. All activities of the parties to this Subcontract with regard to classified information shall be consistent with and subject to the
Security Regulations of the Department of Defense, NISPOM, 5200.4, or agency specific security regulations. 
  

	11.	TERMINATION OF SUBCONTRACT; SURVIVAL OF CERTAIN TERMS AND OBLIGATIONS. 

 A. Mutual Written Consent. This Subcontract may be terminated immediately by mutual written consent of both parties. 
 B. Uncured Breach. If either party materially breaches any of the obligations imposed upon it hereunder, the other party shall have the right at its option, to terminate this Subcontract immediately by
written notice if such failure is not cured within ten (10) days following receipt of written notice of such failure from the non-breaching party. 
 C. Concurrency with GSA Schedule. Unless earlier terminated as set forth in this Section 11, the term of this Subcontract shall be concurrent with the term of the QuadraMed GSA Schedule for so long
as the EPS product is part of such schedule, including any extension thereto or renewal thereof, as authorized by the GSA. The parties acknowledge the ramifications of EPS product being on the QuadraMed GSA Schedule include the requirement that
QuadraMed stand ready to perform any order by any Federal agency off that schedule; DSS agrees to cooperate with QuadraMed for such orders, regardless of the purchasing Federal agency, during the term of this Subcontract. Notwithstanding the
foregoing, neither party shall be restricted in any way by this Subcontract in its marketing activities to any Federal agency other than the Department of Veterans Affairs. Such marketing and sales activities outside the Department of Veterans
Affairs may include, without limitation, bidding or otherwise entering into contract activities either alone or in concert with third parties, regardless of whether such activities are in competition with the other party to this Subcontract.

 D. Bankruptcy, etc. Either party may immediately terminate this Subcontract by delivering prior written notice to the other
party upon (i) the institution of insolvency, receivership or bankruptcy proceedings or any other proceedings for the settlement of debts of the other party, (ii) the making of an assignment for the benefit of creditors by the other party,
or (iii) the dissolution of the other party. 
 E. Return of Products and Termination of Rights. In the event of a
termination under this Section 11, DSS shall continue to provide all warranty services consistent with the published warranty for Products licensed to the U. S. Government under the BPA during the Term, and to assume full responsibility for all
post-warranty maintenance work so long as DSS has received payment in full on all sublicenses granted to the Customer. All sublicenses granted to Customer prior to the termination of this Subcontract shall survive the termination of this Subcontract
for their existing term as long as DSS has received payment in full on all sublicenses granted to the Customer and such Customer continues to abide by the terms and conditions of the Software License Agreement. Notwithstanding anything to the
contrary, QuadraMed shall have no further rights in connection with the Products upon termination of this Subcontract by DSS as a result of a QuadraMed material breach as set forth in Section 11(B) above. 
 F. Prior Obligations. Neither the expiration nor termination of this Subcontract shall release QuadraMed from the obligation to pay any sum
that then may be owing to DSS for products or software delivered to, and accepted by, QuadraMed or the Customer. Neither the expiration nor termination of this Subcontract shall release either party from the obligation to perform any other 

  

 Page 9 of 16 

 
duty for or on behalf of the Customer or to discharge any other liability that had been incurred prior thereto. For purposes of this Section II(F),
“duty” means all obligations specifically set forth in this Subcontract Subject to the above provisions of this Section 11(F), however, neither party shall by reason of the expiration or termination of this Subcontract be liable to
the other for compensation or damage on account of the loss of present or prospective profits on sales or anticipated sales, or expenditures, investments or commitments made in connection therewith or in connection with the establishment,
development or maintenance of QuadraMed’s or DSS’ business or goodwill. 
 G. Survival. The provisions of Sections
3(D), 6(1), 10, 11, 12, and 13 shall survive the termination of this Subcontract for any reason. All other rights and obligations of the parties shall cease upon termination of this Subcontract. 
  

	12.	INDEPENDENT CONTRACTORS. 

 DSS and QuadraMed shall
be deemed independent contractors hereunder and neither party shall be nor hold itself out as an employee or agent of the other. Each party acknowledges that it does not have any authority to act for, or on behalf of, or in the name of the other or
to bind or to commit the other in any manner whatsoever Notwithstanding anything to the contrary, QuadraMed shall have no further rights in connection with the Products upon termination of this Subcontract by DSS as a result of a QuadraMed material
breach as set forth in Section II(B) above except to the extent authorized by this Subcontract. Each party further acknowledges that it is not authorized to make any representations or warranties on behalf of the other, except as expressly agreed to
in writing by the other party in this Subcontract or otherwise. 
  

	13.	MISCELLANEOUS. 

 A. Compliance with
Laws. DSS and QuadraMed acknowledge that there are several regulations and civil and criminal laws governing procurement by the U. S. Government, particularly those relating to procurement integrity, prohibited lobbying, major fraud, false
claims, suspension and debarment, false statements, trade agreements act, and similar requirements. DSS and QuadraMed agree to comply with these laws and regulations when engaged in the process of selling products and services to the Customer. In
order to facilitate the exchange of information in accordance with this Subcontract and in conformity with the laws and regulations of the United States relating to the exportation of technical data, both parties agree to fully comply with all
relevant laws and regulations of the United States Government and to ensure that no violation of such laws or regulations shall occur. Without limiting the foregoing, the parties acknowledge and agree that they may be subject to regulations of the
U.S. Department of Commerce, Bureau of Export Administration, which prohibit the export or diversion of certain products and technologies to certain countries. DSS and QuadraMed agree that they shall not export or divert the Products or Software
without fully complying with all relevant laws and regulations, including without limitation, the Export Administration Act of 1979, as amended, any successor legislation, and the Export Administration Regulations issued by the Department of
Commerce. In addition, this Subcontract is subject to the applicable FAR clauses set forth at Exhibit D (“FAR Flow-down Clauses”). 
 B. No Assignment. Without the written consent of the other party, which shall not be unreasonably withheld, neither this Subcontract nor any right, obligation or other interest therein shall be delegated, sublicensed, assigned
or otherwise transferred by the other party, by operation of law or otherwise. Either party may, however, assign this Subcontract to a parent, subsidiary, affiliate or successor in interest or as part of a merger, consolidation, sale of all or
substantially all of its assets or a change in control. 
  

 Page 10 of 16 

 C. Damages. INDEPENDENTLY OF ANY OTHER LIMITATION HEREOF, IT IS AGREED THAT IN NO EVENT
SHALL EITHER PARTY BE LIABLE TO THE OTHER OR ANY THIRD PARTY FOR INDIRECT, SPECIAL, EXEMPLARY, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OF ANY KIND UNDER THIS SUBCONTRACT. 
 D. No Waiver. The failure of either party at any time to require performance by the other party of any provisions hereof shall in no way
affect the full right to require such performance at any time thereafter. Nor shall the waiver by either party of a breach of any provisions hereof be a waiver of any succeeding breach of the same or any other such provisions or be a waiver of the
provision itself. 
 E. Amendments. This Subcontract shall not be modified, terminated or otherwise amended other than by a
signed written agreement of the parties. 
 F. Force Majeure. Neither party shall be responsible for any failure to perform due
to causes beyond their reasonable control, including but not limited to acts of God, war, riot, embargoes, acts of civil or military authorities, acts or failures of suppliers, fires, floods, earthquakes, and strikes or shortages of labor or
materials. The party so affected shall be excused from such performance to the extent that and for so long as performance is prevented, interrupted or delayed thereby. 
 G. Severability. The invalidity or unenforceability of any particular provision of this Subcontract shall not affect the other provisions of this Subcontract and shall be construed in all respects as if
such invalid or unenforceable provision were omitted. 
 H. Notices. Except as expressly set forth in this Subcontract, all
notices, consents, disclosures, and other communications required or permitted to be given hereunder, and all subsequent subcontracts between the parties in connection with, this Subcontract must be given or made, as applicable, in writing by
facsimile or registered or certified mail with return receipt or sent by overnight courier with a reliable tracing system and shall be effective only when received by the other party at its respective address set forth below or, if delivery is
refused or rejected, as of the date of such refusal or rejection: 
  

			
	 If to DSS:
  
 12575 US Hwy 1, Suite 200
 Juno Beach, FL 33408
 Attention: Mark Byers, President
 Telephone: (516) 227-0207
 Fax: (561) 630-0729
	  	 If to QuadraMed:
  
 12110 Sunset Hills Road, Suite 600
 Reston, Virginia 20190-5852
 Attn: Erik J. Goetschi, Senior Director,
  Contracts
 Telephone:
(703) 904-5617
 FAX: (703) 904-5588
  
 With a copy to:
 David W. Wells, Lead Counsel
 12110 Sunset Hills Road, Suite 600
 Reston, VA 20190
 Telephone: (703) 904-5670
 FAX: (703) 742-5300

 Either party may change its address for notices by giving ten (10) days prior written notice
of such change to the other party given in the manner set forth in this section. 
  

 Page 11 of 16 

 I. Entire Subcontract. The exhibits referred to in and attached to this Subcontract are
hereby incorporated into and form part of this Subcontract. This Subcontract, together with the exhibits attached hereto, sets forth the entire agreement and understanding between the parties as to the subject matter hereof and supersedes all prior
writings and discussions between them including without limitation that certain Software Reseller Agreement dated February 2001, and neither party shall be bound by any terms, conditions, definitions, warranties or representations other than as
expressly provided herein, or as duly set forth on or subsequent to the date hereof in writing signed by the party to be bound thereby. 
 The Exhibits are: 
 A-Products; 
 B-Prices; 
 C-Software License; 
 D-Flow-Down Clauses 
 J. Titles, Headings. Titles or captions of sections contained in this Subcontract are inserted
only as a matter of convenience and for reference, and shall not be deemed a part of this Subcontract. 
 K. Governing Law and
Venue. This Subcontract shall be governed by and interpreted in accordance with the laws of the Commonwealth of Virginia without regard to those laws concerning conflicts of law. Any action or proceeding brought to enforce the terms of this
Subcontract shall be brought in the County of Fairfax, Commonwealth of Virginia (if under state law) or the Eastern District of Virginia (if under federal law). Each of the parties hereby submits itself to the exclusive jurisdiction and venue of
such courts for purposes of any such action. 
 L. HIPAA Compliance. To the extent required by the provisions of the Health
Insurance Portability and Accountability Act (“HIPAA”) and the regulations promulgated thereunder, the parties hereby agree to appropriately safeguard protected health information (“PHI”) made available to or obtained by either
of them pursuant to this Agreement. Without limiting the obligations of either party otherwise set forth in this Agreement or imposed by applicable law, each party agrees to comply with applicable requirements of law relating to PHI and with respect
to any task or other activity it performs in connection with this Agreement. Specifically, each party shall: 
 1. use appropriate safeguards
to prevent use or disclosure of PHI; 
 2. report to the other any use or disclosure of PHI of which it becomes aware; and 
 3. make its internal practices, books, and records relating to the use and disclosure of PHI obtained by it pursuant to this Agreement available to the
Secretary of the United States Health & Human Services as required by law. 
  

 Page 12 of 16 

 IN WITNESS HEREOF, the parties hereto have executed this Subcontract as of the date last signed below:

  

									
	Document Storage Systems, Inc.	 		 	QuadraMed Corporation
					
	By:	 	 	 		 	By:	 	 
	Name:	 		 		 	Name:	 	
	Title:	 		 		 	Title:	 	
	Date:	 		 		 	Date:	 	

  

 Page 13 of 16 

 EXHIBIT C 
 SOFTWARE LICENSE AGREEMENT 
 Licensees Name and Address: 
 Licensees Names: 
 QuadraMed Corporation and 
 the United States Dep’t of Veterans Affairs 
 This Software License Agreement (“Agreement”) is entered into between Document Storage Systems, Inc., a Missouri corporation with offices at 12575 US Hwy 1, Suite 200, Juno Beach, Florida 33408 (“DSS” or
“Licensor”) and the Licensees identified above (and their wholly owned subsidiaries) (“Licensees”). In consideration of the mutual obligations described in this Agreement and other good and valuable consideration, the sufficiency
and receipt of which are hereby severally acknowledged, the parties agree as follows: 
 1. Term and Scope. This Agreement shall become
effective as of the date last signed below (“Effective Date”) and shall continue in effect until terminated in accordance with the Subcontract between QuadraMed and DSS dated July 21, 2006 (“Subcontract”). The Scope
of this Agreement is to cover, and to be effective in concurrence with a The BPA Subcontract issued pursuant to the Contract known as VA BPA No. 10l-049AH-005 unless otherwise terminated or cancelled in accordance with the Subcontract. Any
term that is not otherwise defined in this Agreement shall have the same definition as set forth in the Subcontract. 
 2. License. The
Licensees agree that Software and Documentation (as set forth in the Exhibits to the BPA Subcontract and including without limitation the Product as defined under the Subcontract) is “commercial computer software” or “commercial
computer software documentation” and that, absent a written agreement with DSS to the contrary, the Licensees’ rights with respect to such Software or Documentation are, in the case of civilian agency use, Restricted Rights, as defined in
FAR §52.227.19, and if for Department of Defense use, limited by the terms of this Agreement, pursuant to DFARS §227.7202. If the Software includes CPT codes which is commercial technical data and/or computer databases and/or commercial
computer software and/or commercial computer software documentation, as applicable, that were developed exclusively at private expense by DSS or the American Medical Association, 515 N. State Street, Chicago, Illinois, 60610, United States,
Licensees rights to use, modify, reproduce, release, perform, display, or disclose, these technical data and/or computer databases and/or commercial computer software and/or commercial computer software documentation are subject to the Limited
Rights restrictions of DFARS §252.227-7015(b)(2) (June 1995) and/or subject to the restrictions of DFARS §227.7202-1(a) (June 1995) and DFARS §227.7202-3(a) (June 1995), as applicable for Department of Defense procurements and the
Limited Rights restrictions of FAR §52.227-l4 (June 1987) and/or subject to the Restricted Rights provisions of FAR §52.227-14 (June 1987) and FAR §52.227-19 (June 1987), as applicable, and any applicable agency FAR Supplements, for
non-Department of Defense Federal procurements. Notwithstanding anything herein to the contrary, the parties agree that the restricted rights use restrictions of 52.227 that pertain to computer software as defined therein are applicable to Software
hereunder, and the limited rights use restrictions that pertain to computer software documentation as defined therein apply to Documentation hereunder. Specifically, the parties agree that all software and technical data is and has been privately
developed at the expense of Licensor and/or its third party suppliers. 
 3. Documentation. Licensor shall provide Licensees with a full set of
current written Documentation. These documents may be changed from time to time by Licensor, and additional documents may be produced from time to time by Licensor. Licensor shall provide Licensees with copies of such changes and additional
Documentation if applicable. Upon the prior written approval of Licensor, Licensees may make copies of the Documentation for Licensees’ own internal use, provided that the Documentation is reproduced with Licensor’s copyright and trademark
notices. 
  

 Page 14 of 16 

 4. Title; Reserved Rights. Notwithstanding anything to the contrary, Licensor reserves all right, title and
interest in and to the Software and Documentation (including, but not limited to, originals, translations, compilations and partial copies, if any) and except for the limited license rights to the Software and Documentation granted herein, Licensees
acquires no rights in or to the Software or the Documentation. 
 5. License Grant. According to the terms and conditions of this Agreement and
the Subcontract, Licensor hereby grants Licensees a non-exclusive, non-transferable, and restricted license to use the Software (in object code form only) and Documentation solely for Licensees’ internal use in connection with QuadraMed’s
EPS products sublicensed under the BPA. 
 6. Warranty. 
 A. Software. Licensor warrants that the Software shall, for a period of ninety (90) days following the Completion of Functional Test (“Warranty Period”), operate substantially in accordance with Licensor’s
then-current published specifications. In the event that the Software is defective, Licensees shall provide Licensor with written notice of the claimed defect and information sufficient to permit Licensor to recreate the defect. Licensor shall use
best efforts to cure said defect within a reasonable period of time or to replace Licensees’ copy of the Software with another copy of the Software in Licensor’s sole discretion. If Licensor is unable to make the Software operate
substantially in accordance with Licensor’s then-current published specifications, Licensees shall be entitled to recover the fees paid to Licensor for the Software license and Licensees shall cease using the applicable Software. After
expiration of the Software Warranty Period, all Support, Maintenance, and Updates will be available only through Licensor’s Software Support and Maintenance Plan, as described in this Agreement, for so long as Licensees keep their account
current. These shall be Licensees’ sole and exclusive remedies. This warranty shall not apply if: (I) the Software was not used in accordance with Licensor’s then-current published specifications; (2) the Software was altered,
modified or converted by Licensees; (3) Licensees’ computer(s) malfunctioned and the malfunction caused the defect; (4) accessories, attachment(s), or other products not furnished by Licensor were used in combination with the
Software; (5) the Software or Equipment is subjected to misuse or alteration, is improperly installed, improperly maintained or improperly operated (installation, maintenance, or operation not in accordance with the Documentation shall be
conclusively presumed to be improper); (6) the Software or Equipment are damaged or fail to operate properly due to causes other than ordinary use; (7) the Software or Equipment have been altered (including without limitation any deviation
from circuit or structural design as provided by Licensor or installation or removal of Licensor features) by anyone other than Licensor or a service agency designated in writing by Licensor; (8) Licensees has not provided or maintained a
proper installation environment with all facilities and equipment prescribed in the Documentation or otherwise prescribed by Licensor (including without limitation failure to provide adequate electrical power, air conditioning, or humidity control);
(9) Licensees have used supplies or materials in connection with the Software not meeting the standards set forth in the Documentation or otherwise communicated by Licensor to Licensees; (10) the Software has been serviced or repaired by a
party not approved in writing by Licensor; (11) Licensor personnel are not given full, free and safe access to the facility where the Software is installed; or (12) any other cause within the control of Licensees caused the defect or
malfunction. Notwithstanding the foregoing, however, where a loss of data is caused by a confirmed failure of the Software, Licensor agrees to provide reasonable assistance to Licensees in the recovery of data for the period from the latest
Licensees backup of the data until the failure, such period not to exceed twenty-four (24) hours. The foregoing states Licensor’s sole responsibility to Licensees with respect to data loss. 
  

 Page 15 of 16 

 “Completion of Functional Test” means the date upon which the first Functional Test at any of the Equipment
Sites is complete. “Functional Test” means the process of testing the Software to verify that it operates substantially in accordance with Licensor’s then-current published specifications and which may include functionality,
operational, reporting, and integrated testing as specified in the Addendum. 
 B. Services. Licensor warrants that its Software Support and
Maintenance Plan and consulting services will be performed in a manner consistent with generally accepted industry standards. This warranty shall be valid for ninety (90) days from the performance of services. Licensees’ exclusive remedy,
and Licensor’s entire liability for services that do not conform to this warranty, shall be the re-performance of services; or, if Licensor is unable to perform the services as warranted, Licensees shall be entitled to recover the fees paid to
Licensor for the nonconforming services. 
 LICENSOR DOES NOT WARRANT THAT THE FUNCTIONS PERFORMED BY THE SOFTWARE WILL MEET LICENSEES’ REQUIREMENTS,
THAT THE SOFTWARE WILL OPERATE ERROR FREE, THAT IT WILL OPERATE UNINTERRUPTEDLY, THAT IT WILL OPERATE IN COMBINATION WITH OTHER SOFTWARE (EXCEPT AS PERMITTED BY LICENSOR’S THEN-CURRENT PUBLISHED SPECIFICATIONS) OR THAT ALL DEFECTS ARE
CORRECTABLE. ORAL STATEMENTS MADE BY ANY OF THE PARTIES MAY NOT BE RELIED UPON AND ARE NOT A PART OF THIS AGREEMENT. THE FOREGOING WARRANTIES ARE EXCLUSIVE AND IN LIEU OF ALL OTHER WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT
LIMITED TO, THE WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INTERFERENCE WITH QUIET ENJOYMENT, ACCURACY OF THE DATA AND NON-INFRINGEMENT. LICENSOR WARRANTS THIRD PARTY SOFTWARE, PRODUCTS OR EQUIPMENT ONLY TO THE EXTENT THAT
SUCH THIRD PARTY HAS WARRANTED THEIR PRODUCT OR EQUIPMENT TO LICENSOR. 
 7. Indemnification. Subject to and without reducing any rights of the
Customer pursuant to FAR 52.227-2, Licensor shall indemnify and hold Licensees harmless from any liabilities, damages or costs (including reasonable attorneys’ fees), or expense incurred by Licensees for any claim, demand, proceeding or action
based on infringement of a United States patent or copyright as a result of Licensees’ use of Software, provided that Licensees (1) have notified Licensor promptly in writing of any such claim or suit against Licensees and cooperates fully
with Licensor, and permits Licensor to defend or settle such claim or suit on behalf of Licensees; (2) have maintained current maintenance fees, without interruption, from the date of this Agreement until the date of such claim; (3) have
not used the Software with other software except as permitted by Licensor’s then-current published specifications and has not modified the Software or taken any other action which nullifies the warranties set forth in Section 6; and
(4) have complied with all of the terms and conditions of this Agreement. Licensor shall have no liability or obligation to Licensees hereunder with respect to any infringement claim based upon (a) the use of a superseded or altered
release of the Software or Documentation if the infringement would have been avoided by the use of a current or an unaltered release of the Software or Documentation that Licensor makes available to Licensees; or (b) the combination, operation
or use of any Software or Documentation furnished under this Agreement with software, hardware or other materials not furnished by Licensor if such infringement would have been avoided by the use of the Software or Documentation without such
software, hardware or other materials. The foregoing states the entire liability of Licensor with respect to the infringement of any United States patent or copyright by the Software or Documentation. Further, if any Software becomes or, in
Licensor’s opinion, is likely to become the subject of any injunction preventing its use as contemplated herein, Licensor may, at its option: (a) procure for Licensees the right to continue using such Software; (b) replace or modify
such Software so that it becomes non-infringing without substantially compromising its functionality; or, if (a) and (b) are not reasonably available to Licensor, then (c) terminate Licensees’ license to the allegedly infringing
Software and pay to Licensees an amount not to exceed the amount of license fees paid by Licensees for the applicable Software. 
  

 Page 16 of 16Inducement Grant Omnibus Incentive Plan

 Exhibit 4.2 
 ECLIPSYS CORPORATION 
 INDUCEMENT GRANT OMNIBUS INCENTIVE PLAN 
 (Implemented July 8, 2009 pursuant to unanimous written consent of Eclipsys’ Board of Directors effective July 7, 2009; shares available
for awards increased on August 3, 2009 from the initial amount of 155,556 to 500,000) 
 Eclipsys Corporation (the
“Company”), a Delaware corporation, hereby establishes and adopts the following Inducement Grant Omnibus Incentive Plan (the “Plan”). 
 1. PURPOSE OF THE PLAN 
 The purpose of the Plan is to provide terms and conditions to govern inducement grants made by the
Company under Section 5635(c)(4) of the NASDAQ Stock Market Rules (“Inducement Grants”). Such Inducement Grants are intended to assist the Company and its Subsidiaries in recruiting and retaining selected individuals to serve as
employees of the Company and its Subsidiaries who are expected to contribute to the Company’s success and to achieve long-term objectives that will benefit stockholders of the Company through the additional incentives inherent in the Awards
hereunder. 
 2. DEFINITIONS 
 2.1.
“Award” shall mean any Option, Stock Appreciation Right, Restricted Stock Award, Restricted Stock Unit, Other Share-Based Award, Performance Award or any other right, interest or option relating to Shares or other property
(including cash) granted pursuant to the provisions of the Plan. 
 2.2. “Award Document” shall mean any agreement,
contract, notice, memorandum or other instrument or document evidencing any Award hereunder, including through an electronic medium. 
 2.3. “Board” shall mean the board of directors of the Company. 
 2.4. “Code” shall
mean the Internal Revenue Code of 1986, as amended from time to time. 
 2.5. “Committee” shall mean the Compensation
Committee of the Board or a subcommittee thereof formed by the Compensation Committee to act as the Committee hereunder. The Committee shall consist of no fewer than two Directors, each of whom is (i) a “Non-Employee Director” within
the meaning of Rule 16b-3 of the Exchange Act, (ii) an “outside director” within the meaning of Section 162(m) of the Code, and (iii) an “independent director” for purpose of the rules of the principal securities
exchange on which the Shares are traded, to the extent required by such rules. 
 2.6. “Covered Employee” shall mean
an employee of the Company or its subsidiaries who is a “covered employee” within the meaning of Section 162(m) of the Code. 
 2.7. “Director” shall mean a non-employee member of the Board. 

 2.8. “Dividend Equivalents” shall have the meaning set forth in
Section 11.5. 
 2.9. “New Employee” shall mean any prospective and newly hired employee conditioned upon, and
effective not earlier than, such person becoming an employee of the Company or any Subsidiary. 
 2.10. “Exchange
Act” shall mean the Securities Exchange Act of 1934, as amended. 
 2.11. “Fair Market Value” shall mean,
with respect to Shares as of any date, the per Share closing price of the Shares (i) if the Shares are listed on a national securities exchange, the closing sale price reported as having occurred on the principal securities exchange on which
the Shares are listed and traded on such date, or, if there is no such sale on that date, then on the last preceding date on which such a sale was reported; (ii) if the Shares are not listed on any national securities exchange but is quoted in
an inter-dealer quotation system on a last sale basis, the final ask price reported on such date, or, if there is no such sale on such date, then on the last preceding date on which a sale was reported; or (iii) if the Shares are not listed on
a national securities exchange nor quoted on an inter-dealer quotation system on a last sale basis, the amount determined by the Committee to be the fair market value of the Shares as determined by the Committee in its sole discretion. The Fair
Market Value of any property other than Shares shall mean the market value of such property determined by such methods or procedures as shall be established from time to time by the Committee. 
 2.12. “Option” shall mean any right granted to a Participant under the Plan allowing such Participant to purchase Shares at such
price or prices and during such period or periods as the Committee shall determine. 
 2.13. “Other Share-Based
Award” shall have the meaning set forth in Section 8.1. 
 2.14. “Participant” shall mean a New
Employee who is selected by the Committee to receive an Award under the Plan. 
 2.15. “Payee” shall have the meaning
set forth in Section 12.2. 
 2.16. “Performance Award” shall mean any Award of Performance Cash, Performance
Shares or Performance Units granted pursuant to Article 9. 
 2.17 “Performance Cash” shall mean any cash incentives
granted pursuant to Article 9 payable to the Participant upon the achievement of such performance goals as the Committee shall establish. 
 2.18. “Performance Period” shall mean the period established by the Committee during which any performance goals specified by the Committee with respect to a Performance Award are to be measured. 
 2.19. “Performance Share” shall mean any grant pursuant to Article 9 of an Award valued by reference to a designated number
of Shares, which value will be paid to the Participant upon achievement of such performance goals as the Committee shall establish. 
  

 - 2 - 

 2.20. “Performance Unit” shall mean any grant pursuant to Article 9 of an Award
valued by reference to a designated amount of cash or property other than Shares, which value will be paid to the Participant upon achievement of such performance goals during the Performance Period as the Committee shall establish. 
 2.21. “Permitted Assignee” shall have the meaning set forth in Section 11.3. 
 2.22. “Restricted Stock” shall mean any Share issued with the restriction that the holder may not sell, transfer, pledge or
assign such Share and with such other restrictions as the Committee, in its sole discretion, may impose (including any restriction on the right to vote such Share and the right to receive any dividends), which restrictions may lapse separately or in
combination at such time or times, in installments or otherwise, as the Committee may deem appropriate. 
 2.23. “Restricted
Stock Award” shall have the meaning set forth in Section 7.1. 
 2.24 “Restricted Stock Unit” means an
Award that is valued by reference to a Share, which value may be paid to the Participant by delivery of such property as the Committee shall determine, including without limitation, cash or Shares, or any combination thereof, and that has such
restrictions as the Committee, in its sole discretion, may impose, including without limitation, any restriction on the right to retain such Awards, to sell, transfer, pledge or assign such Awards, and/or to receive any cash Dividend Equivalents
with respect to such Awards, which restrictions may lapse separately or in combination at such time or times, in installments or otherwise, as the Committee may deem appropriate, 
 2.25 “Restricted Stock Unit Award” shall have the meaning set forth in Section 7.1. 
 2.26. “Shares” shall mean the shares of common stock of the Company, par value $0.01 per share. 
 2.27. “Stock Appreciation Right” shall mean the right granted to a Participant pursuant to Article 6. 
 2.28. “Subsidiary” shall mean any corporation (other than the Company) or limited liability company, or comparable foreign entity
(each a “Covered Entity”) in an unbroken chain of Covered Entities beginning with the Company if, at the relevant time each of the Covered Entities other than the last Covered Entity in the unbroken chain owns stock or other equity
interests possessing 50% or more of the total combined voting power of all classes of stock and other equity interests in one of the other Covered Entities in the chain. 
 3. SHARES SUBJECT TO THE PLAN 
 3.1 Number of Shares. (a) Subject to adjustment as
provided in Section 11.2, a total of 500,000 Shares shall be authorized for grant under the Plan. The Board may in its discretion increase the number of Shares available for Awards under the Plan from time to time. 
 (b) If any Shares subject to an Award are forfeited or expire or an Award is settled for cash (in whole or in part), the Shares subject to such Award
shall, to the extent of such forfeiture, expiration or cash settlement, again be available for Awards under the Plan. Notwithstanding anything to the contrary contained herein, the following Shares shall not be added to the Shares authorized 

  

 - 3 - 

 
for grant under paragraph (a) of this Section: (i) Shares tendered by the Participant or withheld by the Company in payment of the purchase price
of an Option, (ii) Shares tendered by the Participant or withheld by the Company to satisfy any tax withholding obligation with respect to an Award, and (iii) Shares subject to a Stock Appreciation Right that are not issued in connection
with the stock settlement of the Stock Appreciation Right on exercise thereof. 
 3.2. Character of Shares. Any Shares issued
hereunder may consist, in whole or in part, of authorized and unissued shares, treasury shares or shares purchased in the open market or otherwise. 
 4.
ELIGIBILITY AND ADMINISTRATION 
 4.1. Eligibility. Any New Employee shall be eligible to be selected as a Participant.

 4.2. Administration. (a) The Plan shall be administered by the Committee. The Committee shall have full power and
authority, subject to the provisions of the Plan and subject to such orders or resolutions not inconsistent with the provisions of the Plan as may from time to time be adopted by the Board, to: (i) select the New Employees to whom Awards may
from time to time be granted hereunder; (ii) determine the type or types of Awards, not inconsistent with the provisions of the Plan, to be granted to each New Employee hereunder; (iii) determine the number of Shares to be covered by each
Award granted hereunder; (iv) determine the terms and conditions, not inconsistent with the provisions of the Plan, of any Award granted hereunder; (v) determine whether, to what extent and under what circumstances Awards may be settled in
cash, Shares or other property; (vi) determine whether, to what extent, and under what circumstances cash, Shares, other property and other amounts payable with respect to an Award made under the Plan shall be deferred either automatically or
at the election of the Participant; (vii) determine whether, to what extent and under what circumstances any Award shall be canceled or suspended, provided that no determination may be made after the grant of the Award that would impair the
rights of the Participant in any material respect without the Participant’s written consent; (viii) interpret and administer the Plan and any instrument or agreement entered into under or in connection with the Plan, including any Award
Document; (ix) correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Award in the manner and to the extent that the Committee shall deem desirable to carry it into effect; (x) establish such rules and
regulations and appoint such agents as it shall deem appropriate for the proper administration of the Plan; (xi) determine whether any Award, other than an Option or Stock Appreciation Right, will have Dividend Equivalents; and (xii) make
any other determination and take any other action that the Committee deems necessary or desirable for administration of the Plan. 
 (b)
Decisions of the Committee shall be final, conclusive and binding on all persons or entities, including the Company, any Participant, and any Subsidiary. A majority of the members of the Committee may determine its actions, including fixing the time
and place of its meetings. 
 (c) To the extent not inconsistent with applicable law or the rules and regulations of the principal securities
exchange on which the Shares are traded, the “independent directors” (as defined by the rules of the principal securities exchange on which the Shares are traded) of the Board may exercise any or all of the authority of the Committee under
the Plan. 
  

 - 4 - 

 5. OPTIONS 
 5.1. Grant of Options. Options may be granted hereunder to New Employees either alone or in addition to other Awards granted under the Plan. Any Option shall be subject to the terms and conditions of the Plan and to such
additional terms and conditions, not inconsistent with the provisions of the Plan, as the Committee shall deem desirable. 
 5.2.
Award Documents. All Options shall be evidenced by a written Award Document in such form and containing such terms and conditions as the Committee shall determine which are not inconsistent with the provisions of the Plan. The terms of
Options need not be the same with respect to each Participant. Granting an Option pursuant to the Plan shall impose no obligation on the recipient to exercise such Option. Any individual who is granted an Option pursuant to this Article may hold
more than one Option granted pursuant to the Plan at the same time. 
 5.3. Option Price. The option price per each Share
purchasable under any Option granted pursuant to this Article shall not be less than 100% of the Fair Market Value of one Share on the date of issuance of such Option. 
 5.4. Option Term. The term of each Option shall be fixed by the Committee in its sole discretion; provided that no Option shall be exercisable after the expiration of seven (7) years from the date
the Option is granted, except in the event of death or disability. 
 5.5. Exercise of Options. (a) Vested Options granted
under the Plan may be exercised by the Participant or by a Permitted Assignee thereof (or by the Participant’s executors, administrators, guardian or legal representative, as may be provided in an Award Document) as to all or part of the Shares
covered thereby, by giving notice of exercise to the Company or its designated agent, specifying the number of Shares to be purchased. The notice of exercise shall be in such form, made in such manner, and in compliance with such other requirements
consistent with the provisions of the Plan as the Committee may prescribe from time to time. 
 (b) Unless otherwise provided in an Award
Document, full payment of such purchase price shall be made at the time of exercise and shall be made (i) in cash or cash equivalents (including certified check or bank check or wire transfer of immediately available funds), (ii) by
tendering previously acquired Shares (either actually or by attestation, valued at their then Fair Market Value), (iii) with the consent of the Committee in any instance or through general administrative procedures approved by the Committee, by
delivery of other consideration having a Fair Market Value on the exercise date equal to the total purchase price, (iv) with the consent of the Committee in any instance or through general administrative procedures approved by the Committee, by
withholding Shares otherwise issuable in connection with the exercise of the Option, (v) through any other method specified in an Award Document (including same-day sales through a broker), or (vi) any combination of any of the foregoing.
The notice of exercise, accompanied by such payment, shall be delivered to the Company at its principal business office or such other office as the Committee may from time to time direct, and shall be in such form, containing such further provisions
consistent with the provisions of the Plan, as the Committee may from time to time prescribe. In no event may any Option granted hereunder be exercised for a fraction of a Share. 
  

 - 5 - 

 5.6. Form of Settlement. In its sole discretion, the Committee may provide at the time an
Option is granted that the Shares to be issued upon an Option’s exercise shall be in the form of Restricted Stock or other similar securities. 
 6.
STOCK APPRECIATION RIGHTS 
 6.1. Grant and Exercise. The Committee may provide Stock Appreciation Rights (a) in
conjunction with all or part of any Option granted under the Plan, (b) in conjunction with all or part of any Award (other than an Option) granted under the Plan, or (c) without regard to any Option or other Award in each case upon such
terms and conditions as the Committee may establish in its sole discretion. 
 6.2. Terms and Conditions. Stock Appreciation
Rights shall be subject to such terms and conditions, not inconsistent with the provisions of the Plan, as shall be determined from time to time by the Committee, including the following: 
 (a) Upon the exercise of a Stock Appreciation Right, the holder shall have the right to receive the excess of (i) the Fair Market Value of one Share
on the date of exercise (or such amount less than such Fair Market Value as the Committee shall so determine at any time during a specified period before the date of exercise) over (ii) the grant price of the Stock Appreciation Right on the
date of issuance, which, except in connection with an adjustment provided in Section 11.2, shall not be less than the Fair Market Value of one Share on such date of issuance of the Stock Appreciation Right. 
 (b) The Committee shall determine in its sole discretion whether payment of a Stock Appreciation Right shall be made in cash, in whole Shares or other
property, or any combination thereof. 
 (c) The provisions of Stock Appreciation Rights need not be the same with respect to each recipient.

 (d) The Committee may impose such other conditions or restrictions on the terms of exercise and the grant price of any Stock Appreciation
Right, as it shall deem appropriate. A Stock Appreciation Right shall have (i) a grant price not less than Fair Market Value on the date of grant (subject to the requirements of Section 409A of the Code with respect to a Stock Appreciation
Right granted in conjunction with, but subsequent to, an Option), and (ii) a term not greater than seven (7) years except in the event of death or disability. 
 7. RESTRICTED STOCK AND RESTRICTED STOCK UNITS 
 7.1. Grants. Awards of Restricted Stock
and of Restricted Stock Units may be issued hereunder to New Employees either alone or in addition to other Awards granted under the Plan (a “Restricted Stock Award” or “Restricted Stock Unit Award” respectively), and such
Restricted Stock Awards and Restricted Stock Unit Awards shall also be available as a form of payment of Performance Awards and other earned cash-based incentive compensation. A Restricted Stock Award or Restricted Stock Unit Award shall be 

  

 - 6 - 

 
subject to vesting restrictions during the Vesting Period as specified by the Committee. The Committee has absolute discretion to determine whether any
consideration (other than services) is to be received by the Company or any Subsidiary as a condition precedent to the issuance of Restricted Stock or Restricted Stock Units. 
 7.2. Award Documents. The terms of any Restricted Stock Award or Restricted Stock Unit Award granted under the Plan shall be set forth in a
written Award Document which shall contain provisions determined by the Committee and not inconsistent with the Plan. The terms of Restricted Stock Awards and Restricted Stock Unit Awards need not be the same with respect to each Participant.

 7.3. Rights of Holders of Restricted Stock and Restricted Stock Units. Unless otherwise provided in the Award Document,
beginning on the date of grant of the Restricted Stock Award and subject to execution of the Award Document, the Participant shall become a stockholder of the Company with respect to all Shares subject to the Award and shall have all of the rights
of a stockholder, including the right to vote such Shares and the right to receive distributions made with respect to such Shares. A Participant receiving a Restricted Stock Unit Award shall not possess voting rights with respect to such Award.
Except as otherwise provided in an Award Document any Shares or any other property (other than cash) distributed as a dividend or otherwise with respect to any Restricted Stock Award or Restricted Stock Unit Award as to which the restrictions have
not yet lapsed shall be subject to the same restrictions as such Restricted Stock Award or Restricted Stock Unit Award. 
 7.4
Issuance of Shares. Any Restricted Stock granted under the Plan may be evidenced in such manner as the Board may deem appropriate, including book-entry registration or issuance of a stock certificate or certificates, which certificate or
certificates shall be held by the Company. Such certificate or certificates shall be registered in the name of the Participant and shall bear an appropriate legend referring to the restrictions applicable to such Restricted Stock. 
 8. OTHER SHARE-BASED AWARDS 
 8.1.
Grants. Other Awards of Shares and other Awards that are valued in whole or in part by reference to, or are otherwise based on, Shares or other property (“Other Share-Based Awards”), including deferred stock units, may be
granted hereunder to New Employees either alone or in addition to other Awards granted under the Plan. Other Share-Based Awards shall also be available as a form of payment of other Awards granted under the Plan and other earned cash-based
compensation. Other Share-Based Awards shall be subject to vesting restrictions during the Vesting Period as specified by the Committee. The Committee has absolute discretion to determine whether any consideration (other than services) is to be
received by the Company or any Subsidiary as a condition precedent to the issuance of Other Share-Based Awards. 
 8.2. Award
Documents. The terms of Other Share-Based Awards granted under the Plan shall be set forth in a written Award Document which shall contain provisions determined by the Committee and not inconsistent with the Plan. The terms of such Awards need
not be the same with respect to each Participant. 
  

 - 7 - 

 8.3. Payment. Except as may be provided in an Award Document, Other Share-Based Awards may
be paid in cash, Shares, other property, or any combination thereof, in the sole discretion of the Committee. Other Share-Based Awards may be paid in a lump sum or in installments or, in accordance with procedures established by the Committee, on a
deferred basis subject to the requirements of Section 409A of the Code. 
 9. PERFORMANCE AWARDS 
 9.1. Grants. Performance Awards in the form of Performance Cash, Performance Shares or Performance Units, as determined by the Committee in
its sole discretion, may be granted hereunder to New Employees, for no consideration or for such minimum consideration as may be required by applicable law, either alone or in addition to other Awards granted under the Plan. The performance goals to
be achieved for each Performance Period shall be conclusively determined by the Committee. 
 9.2. Award Documents. The terms
of any Performance Award granted under the Plan shall be set forth in a written Award Document which shall contain provisions determined by the Committee and not inconsistent with the Plan, including whether such Awards shall have Dividend
Equivalents. The terms of Performance Awards need not be the same with respect to each Participant. 
 9.3. Terms and
Conditions. The performance criteria to be achieved during any Performance Period and the length of the Performance Period shall be determined by the Committee upon the grant of each Performance Award. The amount of the Award to be distributed
shall be conclusively determined by the Committee. 
 9.4. Payment. Except as provided in Article 11 or as may be provided in
an Award Document, Performance Awards will be distributed only after the end of the relevant Performance Period. Performance Awards may be paid in cash, Shares, other property, or any combination thereof, in the sole discretion of the Committee.
Performance Awards may be paid in a lump sum or in installments following the close of the Performance Period or, in accordance with procedures established by the Committee, on a deferred basis subject to the requirements of Section 409A of the
Code. 
 10. CHANGE IN CONTROL PROVISIONS 
 10.1. Impact on Certain Awards. Award Documents or any other written agreement between the Participant and the Company may provide that in the event of a Change in Control of the Company (as defined in Section 10.3):
(i) Options and Stock Appreciation Rights outstanding as of the date of the Change in Control shall be cancelled and terminated without payment if the Fair Market Value of one Share as of the date of the Change in Control is less than the per
Share Option exercise price or Stock Appreciation Right grant price, and (ii) all Performance Awards shall be considered to be earned and payable (either in full or pro rata based on the portion of Performance Period completed as of the date of
the Change in Control), and any limitations or other restrictions shall lapse and such Performance Awards shall be immediately settled or distributed, or canceled if of no value. 
  

 - 8 - 

 10.2. Assumption or Substitution of Certain Awards. 
 (a) Unless otherwise provided in an Award Document or another written agreement between the Participant and the Company, in the event of a Change in
Control of the Company in which the successor company assumes or substitutes for an Option, Stock Appreciation Right, Restricted Stock Award, Restricted Stock Unit Award or Other Share-Based Award, if a Participant’s employment with such
successor company (or a subsidiary thereof) is terminated within 12 months following such Change in Control (or prior thereto in connection with, the Change in Control) without Cause by the Company or the successor company or by the Participant with
Good Reason: (i) Options and Stock Appreciation Rights outstanding as of the date of such termination of employment (or as of the date of the Change in Control if termination occurred prior to and in connection with the Change in Control) will
immediately vest, become fully exercisable, and may thereafter be exercised for 12 months, (ii) restrictions, limitations and other conditions applicable to Restricted Stock and Restricted Stock Units outstanding as of the date of such
termination of employment (or as of the date of the Change in Control if termination occurred prior to and in connection with the Change in Control) shall lapse and the Restricted Stock and Restricted Stock Units shall become free of all
restrictions and limitations and become fully vested, and (iii) the restrictions, limitations and other conditions applicable to any Other Share-Based Awards or any other Awards outstanding as of the date of such termination of employment (or
as of the date of the Change in Control if termination occurred prior to and in connection with the Change in Control) shall lapse, and such Other Share-Based Awards or such other Awards shall become free of all restrictions, limitations or
conditions and become fully vested and transferable to the full extent of the original grant. For the purposes of this Section 10.2, an Option, Stock Appreciation Right, Restricted Stock Award, Restricted Stock Unit Award or Other Share-Based
Award shall be considered assumed or substituted for if following the Change in Control the Award confers the right to purchase or receive, for each Share subject to the Option, Stock Appreciation Right, Restricted Stock Award, Restricted Stock Unit
Award or Other Share-Based Award immediately prior to the Change in Control, the consideration (whether stock, cash or other securities or property) received in the transaction constituting a Change in Control by holders of Shares for each Share
held on the effective date of such transaction (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares); provided, however, that if such consideration received
in the transaction constituting a Change in Control is not solely common stock of the successor company, the Committee may, with the consent of the successor company, provide that the consideration to be received upon the exercise or vesting of an
Option, Stock Appreciation Right, Restricted Stock Award, Restricted Stock Unit Award or Other Share-Based Award, for each Share subject thereto, will be solely common stock of the successor company substantially equal in fair market value to the
per share consideration received by holders of Shares in the transaction constituting a Change in Control. The determination of such substantial equality of value of consideration shall be made by the Committee in its sole discretion and its
determination shall be conclusive and binding. 
 (b) Unless otherwise provided in an Award Document or another written agreement between the
Participant and the Company, in the event of a Change in Control of the Company to the extent the successor company does not assume or substitute (as described in Section 10.2(a)) for an Option, Stock Appreciation Right, Restricted Stock Award,
Restricted Stock Unit Award or Other Share-Based Award: (i) those Options and Stock Appreciation Rights outstanding as of the date of the Change in Control that are not assumed or substituted for shall immediately vest and become fully
exercisable, (ii) restrictions, limitations and other conditions 

  

 - 9 - 

 
applicable to Restricted Stock and Restricted Stock Units that are not assumed or substituted for shall lapse and the Restricted Stock and Restricted Stock
Units shall become free of all restrictions and limitations and become fully vested, and (iii) the restrictions, limitations and other conditions applicable to any Other Share-Based Awards or any other Awards that are not assumed or substituted
for shall lapse, and such Other Share-Based Awards or such other Awards shall become free of all restrictions, limitations or conditions and become fully vested and transferable to the full extent of the original grant. 
 (c) The Committee, in its discretion, may determine that, upon the occurrence of a Change in Control of the Company, all outstanding Awards, other than
Restricted Stock, shall terminate , and that immediately before such termination such Award may be exercised, to the extent exercisable, and/or that each Participant shall receive, with respect to each Share subject to such Award, an amount equal to
the excess of the Fair Market Value of such Share immediately prior to the occurrence of such Change in Control over the exercise price per share, if any, of such Award; such amount to be payable in cash, in one or more kinds of stock or property
(including the stock or property, if any, payable in the transaction) or in a combination thereof, as the Committee, in its discretion, shall determine. 
 10.3. Change in Control. For purposes of the Plan, unless otherwise provided in an Award Document or another written agreement between the Participant and the Company, Change in Control means the
occurrence of any one of the following events: 
 (a) During any twenty-four (24) month period, individuals who, as of the beginning of
such period, constitute the Board (the “Incumbent Directors”) cease for any reason to constitute at least a majority of the Board, provided that any person becoming a director subsequent to the beginning of such period whose election or
nomination for election was approved by a vote of at least a majority of the Incumbent Directors then on the Board (either by a specific vote or by approval of the proxy statement of the Company in which such person is named as a nominee for
director, without written objection to such nomination) shall be an Incumbent Director; provided, however, that no individual initially elected or nominated as a director of the Company as a result of an actual or threatened election
contest with respect to directors or as a result of any other actual or threatened solicitation of proxies by or on behalf of any person other than the Board shall be deemed to be an Incumbent Director; 
 (b) Any “person” (as such term is defined in the Exchange Act and as used in Sections 13(d)(3) and 14(d)(2) of the Exchange Act) is or
becomes a “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing 50% or more of the combined voting power of the Company’s then outstanding
securities eligible to vote for the election of the Board (the “Company Voting Securities”); provided, however, that the event described in this paragraph (b) shall not be deemed to be a Change in Control by virtue of
any of the following acquisitions: (i) by the Company or any Subsidiary, (ii) by any employee benefit plan (or related trust) sponsored or maintained by the Company or any Subsidiary, (iii) by any underwriter temporarily holding
securities pursuant to an offering of such securities, (iv) pursuant to a Non-Qualifying Transaction, as defined in paragraph (c), or (v) by any person of Voting Securities from the Company, if a majority of the Incumbent Board approves in
advance of or within 30 days after the acquisition of beneficial ownership of 50% or more of Company Voting Securities by such person; 
  

 - 10 - 

 (c) The consummation of a merger, consolidation, statutory share exchange or similar form of corporate
transaction involving the Company or any of its subsidiaries (a “Business Combination”), unless immediately following such Business Combination: (i) more than 50% of the total voting power of (A) the corporation resulting from
such Business Combination (the “Surviving Corporation”), or (B) if applicable, the ultimate parent corporation that directly or indirectly has beneficial ownership of at least 90% of the voting securities eligible to elect directors
of the Surviving Corporation (the “Parent Corporation”), is represented by Company Voting Securities that were outstanding immediately prior to such Business Combination (or, if applicable, is represented by securities into which such
Company Voting Securities were converted pursuant to such Business Combination), (ii) no person (other than any employee benefit plan (or related trust) sponsored or maintained by the Surviving Corporation or the Parent Corporation), is or
becomes the beneficial owner, directly or indirectly, of 50% or more of the total voting power of the outstanding voting securities eligible to elect directors of the Parent Corporation (or, if there is no Parent Corporation, the Surviving
Corporation) and (iii) at least a majority of the members of the board of directors of the Parent Corporation (or, if there is no Parent Corporation, the Surviving Corporation) following the consummation of the Business Combination were
Incumbent Directors at the time of the Board’s approval of the execution of the initial agreement providing for such Business Combination (any Business Combination which satisfies all of the criteria specified in (i), (ii) and
(iii) above shall be deemed to be a “Non-Qualifying Transaction”); 
 (d) The stockholders of the Company approve a
plan of complete liquidation or dissolution of the Company or the consummation of a sale of all or substantially all of the Company’s assets; or 
 (e) The occurrence of any other event that the Board determines by a duly approved resolution constitutes a Change in Control. 
 Notwithstanding the foregoing, a Change in Control shall not be deemed to occur solely because any person acquires beneficial ownership of more than 50% of the Company Voting Securities as a result of the acquisition of Company Voting
Securities by the Company which reduces the number of Company Voting Securities outstanding; provided, that a Change in Control of the Company shall then occur if after such acquisition by the Company such person becomes the beneficial
owner of additional Company Voting Securities that increases the percentage of outstanding Company Voting Securities beneficially owned by such person at a level above 50%, other than in connection with the acquisition of stock in a public offering
by the Company. 
 10.4. Cause. For purposes of the Plan, unless otherwise provided in an Award Document or employment
agreement, Cause shall mean (i) willful failure by the Participant which is not cured within 30 days after written notice to the Participant from the Company to perform his or her material responsibilities to the Company, or (ii) willful
misconduct by the Participant which results in material harm to the Company. The Participant shall be considered to have been discharged for Cause if the Company determines within 30 days after the Participant’s resignation, that discharge for
Cause was warranted. 
  

 - 11 - 

 10.5. Good Reason. For purposes of the Plan, unless otherwise provided in an Award Document
or employment agreement, Good Reason shall mean (i) any significant diminution in the Participant’s responsibilities from and after the date of the Change in Control, or (ii) any reduction in the annual salary or target incentive cash
compensation of the Participant from and after the date of the Change in Control. 
 11. GENERALLY APPLICABLE PROVISIONS 
 11.1. Amendment and Termination of the Plan. The Board may, from time to time, alter, amend, suspend or terminate the Plan as it shall deem
advisable, subject to any requirement for stockholder approval imposed by applicable law, including the rules and regulations of the principal securities market on which the Shares are traded; provided that the Board may not amend the Plan in any
manner that would result in noncompliance with Rule 16b-3 of the Exchange Act In addition, no amendments to, or termination of, the Plan shall impair the rights of a Participant in any material respect under any Award previously granted without such
Participant’s consent. 
 11.2. Adjustments. Except to the extent that Section 10.2 is applicable, in the event of
any merger, reorganization, consolidation, recapitalization, dividend or distribution (whether in cash, shares or other property, other than a regular cash dividend), stock split, reverse stock split, spin-off or similar transaction or other change
in corporate structure affecting the Shares or the value thereof, such adjustments and other substitutions shall be made to the Plan and to Awards as the Committee deems equitable or appropriate taking into consideration the accounting and tax
consequences, including such adjustments in the aggregate number, class and kind of securities that may be delivered under the Plan, the maximum number of Shares that may be issued in the aggregate or to any one Participant, in the number, class,
kind and option or exercise price of securities subject to outstanding Awards granted under the Plan (including, if the Committee deems appropriate, the substitution of similar options to purchase the shares of, or other awards denominated in the
shares of, another company) as the Committee may determine to be appropriate; provided, however, that the number of Shares subject to any Award shall always be a whole number. 
 11.3. Transferability of Awards. Except as provided below, no Award and no Shares that have not been issued or as to which any applicable
restriction, performance or deferral period has not lapsed, may be sold, assigned, transferred, pledged or otherwise encumbered, other than by will or the laws of descent and distribution, and such Award may be exercised during the life of the
Participant only by the Participant or the Participant’s guardian or legal representative. To the extent and under such terms and conditions as determined by the Committee, a Participant may assign or transfer an Award (each transferee thereof,
a “Permitted Assignee”) to (i) the Participant’s spouse, children or grandchildren (including any adopted and step children or grandchildren), parents, grandparents or siblings, (ii) to a trust for the benefit of one or more
of the Participant or the persons referred to in clause (i), (iii) to a partnership, limited liability company or corporation in which the Participant or the persons referred to in clause (i) are the only partners, members or shareholders
or (iv) for charitable donations; provided that such Permitted Assignee shall be bound by and subject to all of the terms and conditions of the Plan and the Award Document relating to the transferred Award and shall execute an agreement
satisfactory to the Company evidencing such obligations; and provided further that such Participant shall remain bound by the terms and conditions of the Plan. The Company shall cooperate with any Permitted Assignee and the Company’s transfer
agent in effectuating any transfer permitted under this Section. 
  

 - 12 - 

 11.4. Termination of Employment. The Committee shall determine and set forth in each Award
Document whether any Awards granted in such Award Document will continue to be exercisable, and the terms of such exercise, on and after the date that a Participant ceases to be employed by or to provide services to the Company or any Subsidiary
(including as a Director), whether by reason of death, disability, voluntary or involuntary termination of employment or services, or otherwise. The date of termination of a Participant’s employment or services will be determined by the
Committee, which determination will be final. Except as may be provided in the Award Document issued to a Participant, or any other written agreement between the Participant and the Company, (i) Awards issued to a Participant stop vesting upon
cessation of the Participant’s employment; and (ii) Awards that have vested at the time of cessation of employment and provision of services may be exercised for up to 90 days thereafter and will then terminate. 
 11.5. Deferral; Dividend Equivalents. The Committee shall be authorized to establish procedures pursuant to which the payment of any
Award may be deferred. Subject to the provisions of the Plan and any Award Document, the recipient of an Award other than an Option or Stock Appreciation Right may, if so determined by the Committee, be entitled to receive, currently or on a
deferred basis, cash, stock or other property dividends, or cash payments in amounts equivalent to cash, stock or other property dividends on Shares (“Dividend Equivalents”) with respect to the number of Shares covered by the Award, as
determined by the Committee, in its sole discretion. The Committee may provide that such amounts and Dividend Equivalents (if any) shall be deemed to have been reinvested in additional Shares or otherwise reinvested and may provide that such amounts
and Dividend Equivalents are subject to the same vesting or performance conditions as the underlying Award. 
 12. MISCELLANEOUS 
 12.1. Award Documents. Each Award Document shall either be (a) in writing in a form approved by the Committee and executed by the
Company by an officer duly authorized to act on its behalf, or (b) an electronic notice in a form approved by the Committee and recorded by the Company (or its designee) in an electronic recordkeeping system used for the purpose of tracking one
or more types of Awards as the Committee may provide; in each case and if required by the Committee, the Award Document shall be executed or otherwise electronically accepted by the recipient of the Award in such form and manner as the Committee may
require. The Committee may authorize any officer of the Company to execute any or all Award Documents on behalf of the Company. The Award Document shall set forth the material terms and conditions of the Award as established by the Committee
consistent with the provisions of the Plan. 
 12.2. Tax Withholding. The Company shall have the right to make all payments or
distributions pursuant to the Plan to a Participant (or a Permitted Assignee thereof) (any such person, a “Payee”) net of any applicable federal, state and local taxes required to be paid or withheld as a result of (a) the grant of
any Award, (b) the exercise of an Option or Stock Appreciation Right, (c) the delivery of Shares or cash, (d) the lapse of any restrictions in connection with any Award or (e) any other event occurring pursuant to the Plan. The
Company or any Subsidiary shall have the right to withhold from wages or other amounts otherwise payable to such 

  

 - 13 - 

 
Payee such withholding taxes as may be required by law, or to otherwise require the Payee to pay such withholding taxes. If the Payee shall fail to make such
tax payments as are required, the Company or its Subsidiaries shall, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to such Payee or to take such other action as may be necessary to
satisfy such withholding obligations. The Committee shall be authorized to establish procedures for election by Participants to satisfy such obligation for the payment of such taxes by tendering previously acquired Shares (either actually or by
attestation, valued at their then Fair Market Value), or by directing the Company to retain Shares (up to the Participant’s minimum required tax withholding rate or such other rate that will not cause an adverse accounting consequence or cost)
otherwise deliverable in connection with the Award. 
 12.3. Right of Discharge Reserved; Claims to Awards. Nothing in the Plan
nor the grant of an Award hereunder shall confer upon any New Employee the right to continue in the employment or service of the Company or any Subsidiary or affect any right that the Company or any Subsidiary may have to terminate the employment or
service of (or to demote or to exclude from future Awards under the Plan) any such New Employee at any time for any reason. Except as specifically provided by the Committee, the Company shall not be liable for the loss of existing or potential
profit from an Award in the event of termination of an employment or other relationship. No New Employee or Participant shall have any claim to be granted any Award under the Plan, and there is no obligation for uniformity of treatment of New
Employees or Participants under the Plan. 
 12.4. Cancellation of Award; Forfeiture of Gain. Notwithstanding anything to the
contrary contained herein, an Award Document or another written agreement between the Participant and the Company may provide that (a) if the Participant, without the consent of the Company, while employed by the Company or any Subsidiary or
after termination of such employment or service, establishes a relationship with a competitor of the Company or any Subsidiary or engages in activity that is in conflict with or adverse to the interest of the Company or any Subsidiary (including
conduct contributing to any financial restatements or financial irregularities), or otherwise breaches any legal or contractual duty or obligation to the Company or any Subsidiary, as determined by the Committee in its sole discretion, or
(b) if within the time period specified in the Award Document or other agreement the Participant establishes a relationship with a competitor or engages in an activity referred to in the preceding sentence, then the Company may cancel any one
or more Awards and the Participant will forfeit any gain realized on the vesting or exercise of the Award or Awards and must repay such gain to the Company. 
 12.5. Stop Transfer Orders. All certificates for Shares delivered under the Plan pursuant to any Award shall be subject to such stop-transfer orders and other restrictions as the Committee may deem
advisable under the rules, regulations and other requirements of the Securities and Exchange Commission, any stock exchange upon which the Shares are then listed, and any applicable federal or state securities law, and the Committee may cause a
legend or legends to be put on any such certificates to make appropriate reference to such restrictions. 
  

 - 14 - 

 12.6. Nature of Payments. All Awards made pursuant to the Plan are in consideration of
services performed or to be performed for the Company or any Subsidiary, division or business unit of the Company. Any income or gain realized pursuant to Awards under the Plan constitutes a special incentive payment to the Participant and shall not
be taken into account, to the extent permissible under applicable law, as compensation for purposes of any of the employee benefit plans of the Company or any Subsidiary except as may be determined by the Committee or by the Board or board of
directors of the applicable Subsidiary. 
 12.7. Other Plans. Nothing contained in the Plan shall prevent the Board from
adopting other or additional compensation arrangements, subject to stockholder approval if such approval is required; and such arrangements may be either generally applicable or applicable only in specific cases. 
 12.8. Severability. If any provision of the Plan shall be held unlawful or otherwise invalid or unenforceable in whole or in part by a
court of competent jurisdiction, such provision shall (a) be deemed limited to the extent that such court of competent jurisdiction deems it lawful, valid and/or enforceable and as so limited shall remain in full force and effect, and
(b) not affect any other provision of the Plan or part thereof, each of which shall remain in full force and effect. If the making of any payment or the provision of any other benefit required under the Plan shall be held unlawful or otherwise
invalid or unenforceable by a court of competent jurisdiction, such unlawfulness, invalidity or unenforceability shall not prevent any other payment or benefit from being made or provided under the Plan, and if the making of any payment in full or
the provision of any other benefit required under the Plan in full would be unlawful or otherwise invalid or unenforceable, then such unlawfulness, invalidity or unenforceability shall not prevent such payment or benefit from being made or provided
in part, to the extent that it would not be unlawful, invalid or unenforceable, and the maximum payment or benefit that would not be unlawful, invalid or unenforceable shall be made or provided under the Plan. 
 12.9. Construction. As used in the Plan, the words “include” and “including,” and variations thereof,
shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words “without limitation.” 
 12.10. Unfunded Status of the Plan. The Plan is intended to constitute an “unfunded” plan for incentive compensation. With respect to any payments not yet made to a Participant by the Company, nothing contained
herein shall give any such Participant any rights that are greater than those of a general creditor of the Company. In its sole discretion, the Committee or the Board may authorize the creation of trusts or other arrangements to meet the obligations
created under the Plan to deliver the Shares or payments in lieu of or with respect to Awards hereunder; provided, however, that the existence of such trusts or other arrangements is consistent with the unfunded status of the Plan. 
 12.11. Governing Law. The Plan and all determinations made and actions taken thereunder, to the extent not otherwise governed by the Code
or the laws of the United States, shall be governed by the laws of the State of Delaware, without reference to principles of conflict of laws, and construed accordingly. 
 12.12. Effective Date of Plan; Termination of Plan. The Plan shall be effective on the date on which it is adopted by the Board. The Plan shall be null and void and of no effect if the foregoing
condition is not fulfilled and in such event each Award shall, notwithstanding any of the preceding provisions of the Plan, be null and void and of no effect. Awards may be granted under the 

  

 - 15 - 

 
Plan at any time and from time to time on or prior to the tenth anniversary of the effective date of the Plan, on which date the Plan will expire except as
to Awards then outstanding under the Plan. Such outstanding Awards shall remain in effect and be governed by the Plan until they have been exercised or terminated, or have expired. 
 12.13. Foreign Employees. Awards may be granted to Participants who are foreign nationals or employed outside the United States, or both,
on such terms and conditions different from those applicable to Awards to New Employees employed in the United States as may, in the judgment of the Committee, be necessary or desirable in order to recognize differences in local law or tax policy.
The Committee also may impose conditions on the exercise or vesting of Awards in order to minimize the Company’s obligation with respect to tax equalization for New Employees on assignments outside their home country. 
 12.14. Compliance with Section 409A of the Code. This Plan is intended to comply and shall be administered in a manner that is
intended to comply with Section 409A of the Code and shall be construed and interpreted in accordance with such intent. To the extent that an Award or the payment, settlement or deferral thereof is subject to Section 409A of the Code, the
Award shall be granted, paid, settled or deferred in a manner that will comply with Section 409A of the Code, including regulations or other guidance issued with respect thereto, except as otherwise determined by the Committee. Any provision of
this Plan that would cause the grant of an Award or the payment, settlement or deferral thereof to fail to satisfy Section 409A of the Code shall be amended to comply with Section 409A of the Code on a timely basis, which may be made on a
retroactive basis, in accordance with regulations and other guidance issued under Section 409A of the Code. 
 12.15.
Captions. The captions in the Plan are for convenience of reference only, and are not intended to narrow, limit or affect the substance or interpretation of the provisions contained herein. 
  

 - 16 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}]]